Bladder Cancer Treatment
Bladder Cancer Treatment
Bladder cancer is treated along one dividing line: whether the tumour has reached the muscular wall. Non-muscle-invasive disease is treated through the urethra and by instilling drugs directly into the bladder, and the intensity of that treatment is set by the risk group. Muscle-invasive disease is treated by removing the bladder, or by irradiating it together with chemotherapy in a bladder-preserving plan. Advanced disease is treated systemically, and increasingly by a marker rather than by histology alone.
The route by risk group
Because the treatment of bladder cancer turns on the muscle division and then on the risk group, the routes are best set out together before each is described in detail. The table on the overview page gives the same categories in summary; what follows explains what each treatment actually involves.
- Low risk, non-muscle-invasive — complete resection through the urethra, with a single dose of chemotherapy instilled immediately afterwards.
- Intermediate and high risk, non-muscle-invasive — resection, then BCG immunotherapy as an induction course with maintenance doses; a second resection first where the tumour is high grade or muscle was not in the specimen.
- Very high risk — the same, with radical cystectomy offered early, before the disease has a chance to become muscle-invasive.
- Muscle-invasive, localised — chemotherapy before surgery, then cystectomy with lymph node dissection; or chemoradiotherapy after a complete resection if the bladder is to be kept.
- Node-positive and metastatic — systemic treatment, with surgery or radiotherapy reserved for selected situations such as a bleeding tumour or an obstructed kidney.
One point about sequence deserves emphasis because it is where patients most often feel rushed. For high-risk non-muscle-invasive disease, the choice between continuing intravesical treatment and proceeding to cystectomy is a genuine one with arguments on both sides: BCG works in a substantial share of patients and preserves the bladder, while cystectomy removes the risk of progression but carries the consequences of major surgery and urinary diversion. The guidance places cystectomy among the definite options for the highest-risk group because the window in which the disease can be cured closes once it becomes muscle-invasive — which is a reason to set the choice out early, not a reason to make it in a single consultation.
Non-muscle-invasive disease: resection first
For about three-quarters of patients, the tumour has not reached the muscle, and the treatment begins and often ends with transurethral resection — removal of the tumour through the urethra with no abdominal incision. The procedure is both diagnostic and therapeutic: the tumour is removed, the specimen goes to pathology, and how completely it was removed has a direct effect on whether the disease comes back.
Two points determine what happens after the resection. The first is whether the resection was complete: for high-grade or T1 tumours, a second resection a few weeks later is standard, because residual tumour is found in a substantial proportion and the second specimen occasionally shows deeper invasion. The second is the risk group, which decides whether anything further is needed at all — a small, solitary, low-grade tumour may need nothing beyond a single instillation, while a high-grade T1 tumour needs a full course of intravesical treatment and an honest discussion about cystectomy. For intermediate and high-risk disease the value lies in the intravesical course being completed rather than in the resection alone.
For tumours that cannot be completely removed through the urethra, the options move up the ladder to a more extensive resection or to cystectomy. The question is not how aggressive the surgeon is willing to be, but whether the tumour can be removed completely by that route.
One thing is worth understanding clearly: non-muscle-invasive does not mean low risk. The same urothelium continues to produce new tumours, so recurrence is part of the natural course of this disease rather than a sign that the first treatment failed — which is also why follow-up cystoscopy continues for years instead of ending at one clear result.
Intravesical therapy: BCG and chemotherapy
Intravesical treatment means putting a drug directly into the bladder through a catheter, where it acts on the lining with very little absorption into the rest of the body. It exists because the disease is a disease of a surface: the tumour is removed, but the urothelium that produced it remains, and treating that surface reduces the appearance of new tumours.
- A single immediate instillation of chemotherapy — usually mitomycin C, given within hours of the resection for low-risk disease, within 24 hours and ideally within 6, to clear cells that may have been disturbed and reseeded during the operation. Its purpose is to reduce recurrence, and because the drug is in the bladder for a short time, the systemic side effects are minimal.
- BCG immunotherapy — a live attenuated mycobacterial preparation, instilled as an induction course and then as maintenance doses over months or years. It is the standard treatment for intermediate and high-risk non-muscle-invasive disease, and it reduces both recurrence and progression.
- BCG maintenance — the part most often underestimated. The benefit of BCG is tied to the maintenance schedule being completed; a shortened course gives less protection, and stopping early because the side effects are inconvenient is a common reason for recurrence.
- Mitomycin C and other intravesical drugs where BCG is unsuitable or unavailable — also used in some patients to control repeated recurrence, as a bridge to cystectomy or as an alternative to it.
- When BCG does not work — disease recurring after adequate BCG is described as BCG-unresponsive, and the choices are cystectomy, an immune checkpoint inhibitor, or a bladder-instilled gene therapy, depending on what is available and on the tumour.
Side effects are worth stating plainly because they are the reason patients stop. The common ones are urinary frequency, urgency and burning for a day or two after each instillation, and general flu-like feelings; they usually settle. Because BCG contains live organisms, a high fever or a prolonged systemic illness after instillation needs prompt assessment rather than waiting. One distinction is often missed: disease recurring despite an adequate course is a different situation from being unable to continue because of side effects, and the two lead to different next steps. Most patients complete the schedule with management of the symptoms, and the team should be told early if the side effects are making the schedule hard to keep.
Radical cystectomy and urinary diversion
Removal of the bladder — radical cystectomy — is the standard treatment for muscle-invasive disease, and it is also offered for the highest-risk non-muscle-invasive disease. The operation removes the bladder together with the pelvic lymph nodes, and in men the prostate and seminal vesicles, in women the uterus and part of the vagina, because those structures share the same lymphatic drainage. Because the bladder is gone, urine needs a new route out, and that reconstruction is a decision that has to be discussed before surgery rather than after it.
The reconstruction is where patients have a real choice, and it should be made with the patient rather than for them:
- Ileal conduit — a short segment of bowel brings the ureters to an opening on the abdominal wall, and urine drains continuously into an external pouch. It is the most straightforward reconstruction, works for almost everyone, and requires no learning of a new way to urinate, though it does require learning to care for the stoma and the pouch.
- Orthotopic neobladder — a reservoir is constructed from bowel and joined to the urethra, so that urine is passed through the usual route. It depends on the urethra being free of tumour, on kidney function and general condition allowing it, and on the patient being willing to manage it; it requires discipline about emptying on a schedule, including at night, with a risk of incomplete emptying.
- Continent cutaneous diversion — an internal reservoir with an antireflux mechanism, emptied by catheterising a small stoma on the abdominal wall. It avoids an external pouch but is a more complex operation, and suits patients who do not want a pouch but are not candidates for a neobladder.
Two facts about the recovery are usually the ones patients most want to know. The operation is major, with a hospital stay measured in days and a recovery measured in weeks, and it is increasingly performed with a robotic or laparoscopic approach where the tumour permits. And the functional consequences are permanent and manageable rather than temporary: continence and sexual function are affected, and both should be addressed in the plan rather than raised after the operation. Whether a patient can tolerate this operation is a real consideration — for those who cannot, the bladder-preserving route exists.
One further point is worth stating: follow-up does not stop after cystectomy. The upper urinary tract and the urethra belong to the same urothelium, so imaging and, where indicated, urethral checks continue at intervals.
Keeping the bladder
Bladder preservation is a real alternative to cystectomy in the right patient, not a concession for those who refuse surgery. The approach — sometimes called trimodality treatment — has three components: a complete resection of the tumour, radiotherapy to the bladder, and chemotherapy given at the same time to make the tumour more sensitive to the radiation — followed by cystoscopy to confirm that the bladder is clear.
The conditions that make it suitable are specific. The tumour must be able to be completely removed and must not be accompanied by extensive carcinoma in situ; the bladder must function reasonably; and the patient must be fit enough for a course of chemoradiotherapy and committed to cystoscopy at intervals afterwards, because the bladder is kept under surveillance rather than declared clear. Where those conditions hold, the route is offered to patients who cannot tolerate radical cystectomy, and to patients who want to keep the bladder and understand the follow-up obligations that come with it.
Two honest points belong in the conversation. First, cystectomy and chemoradiotherapy are not freely interchangeable — each suits a particular tumour and a particular patient, and the assessment should say which the findings support rather than presenting the choice as purely a matter of preference; where the tumour does not meet the conditions, preserving the bladder comes at the cost of tumour control, which is not in the patient's interest. Second, if the tumour recurs after preservation, cystectomy remains an option, which is one reason the follow-up schedule matters as much as the initial treatment.
Systemic treatment before and after surgery
Chemotherapy given before cystectomy — neoadjuvant treatment — is standard for muscle-invasive disease, and the reason is worth stating: it is the treatment that addresses the microscopic spread that imaging cannot see, and it is given while the patient is still fit enough to tolerate it. The usual regimens are cisplatin-based combinations, either a dose-dense regimen combining methotrexate, vinblastine, doxorubicin and cisplatin, or gemcitabine with cisplatin.
- Neoadjuvant chemotherapy — planned in cycles and lasting about three months, with surgery scheduled once blood counts have recovered. The schedule should be written into the plan rather than communicated one cycle at a time.
- Adjuvant treatment after surgery — used for patients who did not receive chemotherapy beforehand, particularly where the pathology shows nodal involvement or more extensive local disease; it may be chemotherapy or immunotherapy.
- Chemotherapy combined with radiotherapy — in bladder-preserving plans the two are given concurrently, so that the drug makes the tumour more sensitive to the radiation.
- Immune checkpoint inhibitors — used at specific stages of the disease, including in patients who are not fit for platinum chemotherapy and in BCG-unresponsive non-muscle-invasive disease.
One thing is worth asking before treatment starts: whether cisplatin can be given depends on kidney function. Platinum-based chemotherapy is central to the perioperative treatment of muscle-invasive disease and is unsuitable for patients with significantly reduced kidney function, so kidney function results are one of the key pieces of information that determine the sequence of treatment rather than an optional test. When platinum is not available the sequence changes accordingly — and that is a question to settle before surgery, not after it.
Advanced and metastatic disease
Once bladder cancer has spread, the aim of treatment shifts from cure to long-term control, and the drugs available have increased markedly in recent years. Treatment is systemic, and the first-line choice now depends on markers as much as on histology. The options in current use:
- Enfortumab vedotin with pembrolizumab — an antibody-drug conjugate directed at Nectin-4 combined with an immune checkpoint inhibitor, now a first-line option for advanced urothelial carcinoma, having displaced chemotherapy as the default in many settings.
- Platinum-based chemotherapy — gemcitabine with cisplatin where kidney function allows, or with carboplatin where it does not; still used where the combination above is unsuitable, and the choice depends on kidney function and on what has been given before.
- Maintenance immunotherapy — an immune checkpoint inhibitor continued after first-line chemotherapy in patients whose disease has not progressed, which extends the benefit of the initial treatment.
- Erdafitinib — an FGFR inhibitor for tumours with an activating FGFR3 alteration, or an FGFR2/3 fusion, usually after platinum chemotherapy; the reason FGFR testing is worth arranging before treatment.
- Later-line options — further antibody-drug conjugates and, for tumours with DNA repair defects, exploration of targeted treatment.
- Bone-directed treatment — radiotherapy and bone-modifying agents where disease has reached the skeleton, both to control pain and to reduce the risk of fracture.
Two points complete the picture. Local treatment still has a role even in metastatic disease: a tumour that will not stop bleeding, or one obstructing a kidney, may need radiotherapy, resection or a stent alongside the systemic treatment rather than instead of it. And the sequence of agents is a plan rather than a single decision, reviewed as treatment proceeds rather than fixed at the outset.
How the decision is made
Bladder cancer sits at the junction of several specialties, and the treatment that suits a patient is rarely decided by one of them alone. A multidisciplinary review brings together urology, medical oncology, radiation oncology, pathology and imaging — and it has to include the patient's own priorities as well. The decisions that benefit from being made together are these:
- Whether a second resection is needed, and what it should sample
- Which intravesical regimen fits the risk group, and whether BCG is the right choice
- Whether the patient is a candidate for cystectomy, and which diversion is appropriate
- Whether a bladder-preserving plan is open, and whether the tumour meets its conditions
- Whether cisplatin can be given, and what replaces it if not
- Which markers to test, and when the result would change the plan
- What the patient's own priorities are — the wish to keep the bladder, acceptance of a stoma, and the follow-up burden the patient can realistically take on
The value of a multidisciplinary review is that these questions are interdependent: a patient who wants to keep the bladder needs to know whether the tumour permits it, and a patient who cannot have cisplatin needs to know what that does to the sequence of treatment. A written assessment should therefore answer them as a set, and state which findings would change the recommendation. It is also why a single reply to a file that contains the resection pathology, the cytology and the imaging together is more useful than answers to pieces of it sent separately.